1.75
0.06 (3.55%)
0.06 (3.55%)
Upgrade to Real-Time
Premarket
Volume | 6,558 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Gamida Cell Ltd | GMDA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.69 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
27 | 6,558 | - | 1.10 - 4.72 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:20:44 | 10 | $ 1.7485 | USD |
Gamida Cell Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 130.52M | 74.58M | 64.64M | $ - | $ - | -1.52 | -1.20 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 60.50k | 1.20% |
Gamida Cell News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GMDA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.63 | 1.7499 | 1.55 | 1.67 | 415,889 | 0.12 | 7.36% |
1 Month | 1.46 | 1.7499 | 1.4101 | 1.59 | 396,370 | 0.29 | 19.86% |
3 Months | 1.90 | 1.90 | 1.10 | 1.45 | 530,740 | -0.15 | -7.89% |
6 Months | 2.21 | 3.66 | 1.10 | 2.02 | 585,791 | -0.46 | -20.81% |
1 Year | 3.24 | 4.72 | 1.10 | 2.35 | 572,829 | -1.49 | -45.99% |
3 Years | 4.78 | 15.00 | 1.10 | 4.86 | 528,959 | -3.03 | -63.39% |
5 Years | 8.30 | 15.41 | 1.10 | 4.92 | 380,492 | -6.55 | -78.92% |
Gamida Cell Description
Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients. |